Last reviewed 2026-04-23 · How we verify

Ultrix®, Inactivated Split Influenza Vaccine

Ultrix stimulates an immune response against the influenza virus.

Ultrix stimulates an immune response against the influenza virus. Used for Prevention of influenza disease caused by influenza A and B viruses in individuals 6 months of age and older..

At a glance

Mechanism of action

This is achieved through the introduction of inactivated split influenza virus antigens, which trigger the body's immune system to produce antibodies and immune cells that can recognize and fight the virus.

Approved indications

• Prevention of influenza disease caused by influenza A and B viruses in individuals 6 months of age and older.

Common side effects

• Pain, redness, or swelling at the injection site

Key clinical trials

• Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine (PHASE2, PHASE3)
• Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra (PHASE2, PHASE3)
• Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant Women (PHASE3)
• The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years. (PHASE3)
• The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.